A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00537407

Enrollment

Registered

2007-10-01

Start date

2007-09-30

Completion date

2010-04-30

Last updated

2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Keywords

Hepatitis, Hepatitis C

Brief summary

Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients. The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only 40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin can improve the outcome of treatment in this group of patients.

Detailed description

This is a multicentre, open-label, randomized, 5 arm parallel-group, multiple dose study in 50 chronic hepatitis C virus (HCV) genotype 1 non-responders to standard treatment with peg-IFN alpha (2a or 2b) and ribavirin. The entire study lasts a maximum of 96 weeks and consists of a 48- or 72-week treatment period (according to response). A follow-up visit to assess the sustained viral response (SVR) takes place 24 weeks after treatment cessation, i.e., at study Week 72 or 96, or earlier for discontinued study participants. There were 2 parts in the treatment period. Part 1 lasted from Day 1 to Day 29 (Weeks 1 to 4); Part 2 lasted from Week 5 to Week 48 or 72. During Part 1 of treatment (Weeks 1 to 4), participants are randomized to 1 of 5 treatment arms and receive 4 weeks of Debio 025 (alisporivir) monotherapy, Debio 025 combined with standard dose peg-IFNα2a, or 1 of 3 triple therapies combining different doses of Debio 025 with peg-IFNα2a and ribavirin at standard doses. During Part 2 of treatment (Weeks 5 to 48 or 72), participants receive standard doses of peg-IFNα2a/ribavirin dual therapy for 44 or 68 weeks, depending on their response to treatment. At Week 12, participants who do not achieve ≥ 2 log10 decrease in HCV RNA are withdrawn and considered treatment failures. Participants who have undetectable HCV RNA levels and/or ≥ 2 log10 decrease in HCV RNA continue treatment until Week 24. At Week 24, participants who still have detectable HCV RNA levels are withdrawn and considered treatment failures. Participants with undetectable HCV RNA levels at Weeks 12 and 24 continue treatment until Week 48. At Week 24, slow responders (defined as participants with a detectable, but \> 2 log10 decrease in HCV RNA levels at Week 12 and undetectable levels at Week 24) are eligible to continue treatment until Week 72.

Interventions

DRUGDebio 025

Debio 025 supplied as a 100 mg/mL oral solution

DRUGPeg-IFNα2a

Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

DRUGRibavirin

Ribavirin supplied as 200 mg tablets

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Male and female patients between 18 and 60 years of age. * Hepatitis B negative and human immunodeficiency virus (HIV) negative. * Diagnosed with hepatitis C genotype I and not responsive to treatments such as peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks. * Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters within acceptable range. * Females may participate only if they cannot become pregnant, i.e., are surgically sterile, post-menopausal, or using 2 reliable contraceptive methods. * Male patients must be surgically sterile or utilizing a barrier contraceptive method. * For female patients of child bearing potential, negative pregnancy test within 1 week of first investigational product administration.

Exclusion criteria

* Treatment with any investigational drug within 6 months prior to the start of the study. * Ongoing or recent use of antiviral medication within 1 month before the start of the study. * A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or ribavirin. * Presence or history of any severe related disease.

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)	Baseline to Day 29	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.

Secondary

Measure	Time frame	Description
log10 Hepatitis C Virus RNA at Day 29	Day 29	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.
Percentage of Participants With a Rapid Viral Response at Day 29	Day 29	A participant had a rapid viral response if their viral RNA was undetectable (\< 10 IU/mL).
Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)	Baseline to Day 29	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.
Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)	End of treatment (Week 48 or 72)	A participant had an end-of-treatment response if their viral RNA was undetectable (\< 10 IU/mL).
Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)	24 weeks after the end of treatment (Week 72 or 96)	A participant had a sustained viral response if their viral RNA was undetectable (\< 10 IU/mL).
Percentage of Participants With an Early Viral Response at Week 12	Baseline to Week 12	A participant had an early viral response if their viral RNA had decreased ≥ 2 log10 at Week 12 compared to Baseline.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Treatment Arm A Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response Debio 025: Debio 025 supplied as a 100 mg/mL oral solution Peg-IFNα2a: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes Ribavirin: Ribavirin supplied as 200 mg tablets	10
Treatment Arm B Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response Debio 025: Debio 025 supplied as a 100 mg/mL oral solution Peg-IFNα2a: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes Ribavirin: Ribavirin supplied as 200 mg tablets	9
Treatment Arm C Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response Debio 025: Debio 025 supplied as a 100 mg/mL oral solution Peg-IFNα2a: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes Ribavirin: Ribavirin supplied as 200 mg tablets	11
Treatment Arm D Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response Debio 025: Debio 025 supplied as a 100 mg/mL oral solution Peg-IFNα2a: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes Ribavirin: Ribavirin supplied as 200 mg tablets	10
Treatment Arm E Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response Debio 025: Debio 025 supplied as a 100 mg/mL oral solution Peg-IFNα2a: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes Ribavirin: Ribavirin supplied as 200 mg tablets	10
Total	50

Baseline characteristics

Characteristic	Treatment Arm B	Treatment Arm C	Treatment Arm D	Treatment Arm A	Treatment Arm E	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	9 Participants	11 Participants	10 Participants	10 Participants	10 Participants	50 Participants
Age, Continuous	52.6 years STANDARD_DEVIATION 5.94	49.9 years STANDARD_DEVIATION 10.71	48.5 years STANDARD_DEVIATION 9.87	51.4 years STANDARD_DEVIATION 6.62	52.8 years STANDARD_DEVIATION 6.51	51.0 years STANDARD_DEVIATION 8.09
Region of Enrollment United States	9 participants	11 participants	10 participants	10 participants	10 participants	50 participants
Sex: Female, Male Female	5 Participants	5 Participants	5 Participants	3 Participants	3 Participants	21 Participants
Sex: Female, Male Male	4 Participants	6 Participants	5 Participants	7 Participants	7 Participants	29 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	10 / 10	9 / 9	11 / 11	10 / 10	10 / 10
serious Total, serious adverse events	0 / 10	0 / 9	1 / 11	0 / 10	0 / 10

Outcome results

Primary